Gene: TBC1D9
Official Full Name: TBC1 domain family member 9provided by HGNC
Gene Summary: Predicted to enable GTPase activator activity. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO29769 | TBC1D9 Knockout cell line (HeLa) | Human | TBC1D9 | 1:3~1:6 | Negative | Online Inquiry |
KO29770 | TBC1D9 Knockout cell line (HCT 116) | Human | TBC1D9 | 1:2~1:4 | Negative | Online Inquiry |
KO29771 | TBC1D9 Knockout cell line (HEK293) | Human | TBC1D9 | 1:3~1:6 | Negative | Online Inquiry |
KO29772 | TBC1D9 Knockout cell line (A549) | Human | TBC1D9 | 1:3~1:4 | Negative | Online Inquiry |
TBC1D9 Gene Knockout Cell Lines are genetically modified cellular models designed to facilitate the study of TBC1D9, a gene implicated in various biological processes including cell signaling and vesicle trafficking. These cell lines have been engineered through precise CRISPR/Cas9 gene editing techniques to create a complete knockout of the TBC1D9 gene, enabling researchers to investigate the gene's function, its role in diseases, and potential therapeutic targets more effectively and accurately.
The primary mechanism of action lies in the disruption of the TBC1D9 gene, which affects cellular pathways that are critical in regulating endosomal recycling and autophagy. By utilizing these knockout cell lines, scientists can elucidate the downstream effects of TBC1D9 deficiency, including changes in cell morphology, protein expression, and intracellular signaling. This elucidation can lead to a deeper understanding of metabolic disorders and neurodegenerative diseases where TBC1D9 is thought to play a key role.
In terms of scientific importance, TBC1D9 Gene Knockout Cell Lines serve as indispensable tools in both basic and applied research settings, including drug discovery, functional genomics, and pathophysiology studies. Their specific advantages include high-precision gene modification, a controlled genetic environment, and reproducibility of experimental results, which are difficult to achieve with traditional knockdown approaches.
Unlike alternative models, such as siRNA or shRNA-mediated knockdowns, which can result in incomplete suppression and off-target effects, our knockout cell lines provide a robust system to study the complete loss of TBC1D9 function. This specificity is particularly appealing for clinicians and researchers focused on developing targeted therapies based on the precise mechanisms that underlie various diseases associated with the TBC1D9 gene.
Our company prides itself on providing high-quality, reliable biological products tailored for cutting-edge research. With a commitment to advancing scientific understanding, our TBC1D9 Gene Knockout Cell Lines represent a valuable resource for researchers dedicated to unlocking the complexities of gene function and disease mechanisms.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.